On April 14, 2010, the U.S. Food and Drug Administration (FDA) released a warning letter to Novartis Consumer Health, Inc., regarding an email indicated for patients who are currently treating with the pharmaceutical drug Voltaren®Gel (diclofenac sodium topical gel). The warning letter criticizes the design and wording of risk and benefit information. Marketers are urged to review email designs and apply the same scrutiny and standards used for broadcast marketing to email efforts. Marketers should pay special attention to the location and balance of benefit versus risk information, as well as emphasis of efficacy claims.
Download important guidelines for marketers to follow when developing pharmaceutical emails. RTCRM Perspectives Email Marketing FDA Warning Letter 4.23.10
Comments are closed.